` ALCLS (Cellectis SA) vs DAX Index Comparison - Alpha Spread

ALCLS
vs
D
DAX Index

Over the past 12 months, ALCLS has significantly outperformed DAX Index, delivering a return of +108% compared to the DAX Index's +28% growth.

Stocks Performance
ALCLS vs DAX Index

Loading
ALCLS
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
ALCLS vs DAX Index

Loading
ALCLS
DAX Index
Difference
www.alphaspread.com

Performance By Year
ALCLS vs DAX Index

Loading
ALCLS
DAX Index
Add Stock

Competitors Performance
Cellectis SA vs Peers

DAX Index
ALCLS
ABBV
AMGN
GILD
VRTX
Add Stock

Cellectis SA
Glance View

Market Cap
280.6m EUR
Industry
Biotechnology

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

ALCLS Intrinsic Value
2.23 EUR
Overvaluation 43%
Intrinsic Value
Price
Back to Top